Vyepti vs. Imitrex

Vyepti (eptinezumab-jjmr) and Imitrex (sumatriptan) are used to treat and prevent migraine in adults.

Vyepti and Imitrex belong to different drug classes. Vyepti is a calcitonin gene-related peptide antagonist and Imitrex is a selective serotonin receptor agonist (a "triptan").

Side effects of Vyepti that are different from Imitrex include runny or stuffy nose and hypersensitivity reactions (itching, flushing).

Side effects of Imitrex that are different from Vyepti include mild headache (not a migraine), pain or chest tightness, pressure or heavy feeling in any part of your body, weakness, feeling hot or cold, dizziness, spinning sensation, drowsiness, nausea, vomiting, drooling, unusual taste in your mouth after using nasal spray, burning/numbness/pain/irritation in your nose or throat after using nasal spray, and flushing (warmth, redness, or tingling under the skin).

Vyepti may interact with other drugs.

Imitrex may interact with sibutramine, monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), norepinephrine reuptake inhibitors, and ergot-containing medications.

Common side effects of Vyepti include:

• runny or stuffy nose and
• hypersensitivity reactions (itching, flushing)

Common side effects of Imitrex include:

• mild headache (not a migraine),
• pain or chest tightness,
• pressure or heavy feeling in any part of your body,
• weakness,
• feeling hot or cold,
• dizziness,
• spinning sensation,
• drowsiness,
• nausea,
• vomiting,
• drooling,
• unusual taste in your mouth after using nasal spray,
• burning/numbness/pain/irritation in your nose or throat after using nasal spray, or
• flushing (warmth, redness, or tingling under the skin).

Vyepti (eptinezumab-jjmr) is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.

Imitrex (sumatriptan) is a selective serotonin receptor agonist used in oral, intranasal or injectable dosage form to treat migraine headaches. Imitrex is available as a generic drug.

Vyepti may interact with other medicines.

Tell your doctor all medications and supplements you use.

Imitrex may interact with sibutramine (Meridia); monoamine oxidase inhibitors (MAOIs) isocarboxazid (Marplan); selective serotonin reuptake inhibitors, fluoxetine (Prozac) and sertraline (Zoloft), serotonin; norepinephrine reuptake inhibitors, venlafaxine (Effexor)) and duloxetine (Cymbalta); and ergot-containing medications, dihydroergotamine (Migranal) and ergotamine (Methergine).

The recommended dosage of Vyepti is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg.

The maximum single recommended adult dose of Imitrex Injection for the acute treatment of migraine or cluster headache is 6 mg injected subcutaneously. For the treatment of migraine, if side effects are dose limiting, lower doses (1 mg to 5 mg) of Imitrex may be used.